- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Study: Whooping cough vaccine may not prevent infection
- FDA advisory panel to consider OTC status of NSAIDs
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for head lice, the agency said Tuesday.
The FDA approved Natroba (spinosad) topical suspension, made by ParaPro, a privately owned drug company based in Carmel, Ind. The drug is used to treat head lice infestation in patients ages 4 years and older.
“Natroba provides another option for the topical treatment of head lice infestations, which are especially prevalent in the pediatric population,” FDA Office of Drug Evaluation III director Julie Beitz said. “Head lice is a common problem among schoolchildren in the United States.”